Psychiatric Comorbidities in Adults with DiGeorge Syndrome.
Comorbidity
Depression
DiGeorge syndrome
Schizophrenia
Journal
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
ISSN: 1738-1088
Titre abrégé: Clin Psychopharmacol Neurosci
Pays: Korea (South)
ID NLM: 101207332
Informations de publication
Date de publication:
31 Aug 2022
31 Aug 2022
Historique:
received:
22
03
2021
accepted:
26
04
2021
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
26
7
2022
Statut:
ppublish
Résumé
DiGeorge Syndrome (DGS) is a common multisystem disorder associated with deletions on chromosome 22q11.2. Our objective is to evaluate the psychiatric comorbidities and demographics of patients suffering from DGS in a nationally representative dataset on inpatient hospitalizations. The Nationwide Inpatient Sample for the year 2005-2017 was used for this study. Data on patients with DiGeorge syndrome were collected by using the International Classification of Diseases code. Univariate and multi- variate logistic regression analysis was performed. In our study, the average age was 30.4 years (n = 6,563), with 59.9% male, and 61.8% of patients were white. There was a high prevalence of mood disorders (24.7%) and anxiety disorders (16.4%), followed by schizo- phrenia and other psychotic condition (14.0%). In patients with mood disorders, 8% had Major Depressive Disorder, and 7% had bipolar depression. Overall composite of psychiatric comorbidities was present in 2,959 (45.1%) of patients. The mean length of stay was 6.58 days, and 77% of patients had routine discharge to home. In the adjusted analysis, the average length of stay was 8.6 days vs. 6.7 days (p < 0.001) in patients with and without psychiatry comorbidities. In comparison to routine discharge, patients with psychiatry comorbidities were more likely to be discharged to other healthcare facilities (odds ratio [OR]: 1.28, p < 0.001) and discharged against medical advice (OR: 3.45, p < 0.001). Patients with DGS have worse outcomes with a higher rate of discharge to other healthcare facilities and a higher rate of being discharged against medical advice. Further large scale randomize studies are indicated.
Identifiants
pubmed: 35879034
pii: cpn.2022.20.3.498
doi: 10.9758/cpn.2022.20.3.498
pmc: PMC9329110
doi:
Types de publication
Journal Article
Langues
eng
Pagination
498-503Références
Am J Psychiatry. 2010 Aug;167(8):998
pubmed: 20693476
J Affect Disord. 2009 Dec;119(1-3):177-80
pubmed: 19269692
Natl Health Stat Report. 2010 Oct 26;(29):1-20, 24
pubmed: 21086860
Am J Med Genet A. 2019 Nov;179(11):2292-2306
pubmed: 31407842
J Am Acad Child Adolesc Psychiatry. 2009 Nov;48(11):1060-1068
pubmed: 19797984
Dev Med Child Neurol. 2002 Jan;44(1):44-50
pubmed: 11811651
Biol Psychiatry. 2014 Mar 1;75(5):351-60
pubmed: 23992925
Am J Psychiatry. 2014 Jun;171(6):627-39
pubmed: 24577245
Genet Med. 2001 Jan-Feb;3(1):23-9
pubmed: 11339373
J Am Acad Child Adolesc Psychiatry. 2006 May;45(5):596-603
pubmed: 16670654
Eur Child Adolesc Psychiatry. 2020 Aug;29(8):1035-1048
pubmed: 30949827
Dev Disabil Res Rev. 2008;14(1):69-74
pubmed: 18636638
Hum Mol Genet. 2008 Dec 15;17(24):4045-53
pubmed: 18806272
Am J Psychiatry. 2006 Apr;163(4):716-23
pubmed: 16585449
Am J Med Genet B Neuropsychiatr Genet. 2004 Apr 1;126B(1):99-105
pubmed: 15048657
J Pediatr. 2011 Aug;159(2):332-9.e1
pubmed: 21570089
J Am Acad Child Adolesc Psychiatry. 2010 Apr;49(4):333-44
pubmed: 20410726